{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:58:01Z","timestamp":1789178281789,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.7759\/cureus.95260","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:41:02Z","timestamp":1761270062000},"source":"Crossref","is-referenced-by-count":3,"title":["Nivolumab-Induced Hemophagocytic Lymphohistiocytosis (HLH) in a Patient With Metastatic Melanoma: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Ravjot K","family":"Virdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Bitran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Familial Hemophagocytic Lymphohistiocytosis","author":"Zhang K","year":"2006","unstructured":"Zhang K, Astigarraga I, Bryceson Y, et al.. Familial Hemophagocytic Lymphohistiocytosis. GeneReviews\u00ae, Seattle (WA); 2006."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02941-3","article-title":"Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore","volume":"24","author":"Knaak C","year":"2020","unstructured":"Knaak C, Nyvlt P, Schuster FS, et al.. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care. 2020, 24:244. 10.1186\/s13054-020-02941-3","journal-title":"Crit Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14740\/jh1033","article-title":"Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in a patient with squamous cell carcinoma","volume":"11","author":"Marar R","year":"2022","unstructured":"Marar R, Prathivadhi-Bhayankaram S, Krishnan M. Immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in a patient with squamous cell carcinoma. J Hematol. 2022, 11:142-7. 10.14740\/jh1033","journal-title":"J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03585-3","article-title":"Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature","volume":"16","author":"Rubio-Perez J","year":"2022","unstructured":"Rubio-Perez J, Rodr\u00edguez-Perez \u00c1R, D\u00edaz-Bl\u00e1zquez M, Moreno-Garc\u00eda V, D\u00f3mine-G\u00f3mez M. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature. J Med Case Rep. 2022, 16:365. 10.1186\/s13256-022-03585-3","journal-title":"J Med Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04625-3","article-title":"Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review","volume":"24","author":"Zhai C","year":"2024","unstructured":"Zhai C, Jin X, You L, et al.. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review. BMC Geriatr. 2024, 24:32. 10.1186\/s12877-023-04625-3","journal-title":"BMC Geriatr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-020-0050-3","article-title":"Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge","volume":"5","author":"Kalmuk J","year":"2020","unstructured":"Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. Cancers Head Neck. 2020, 5:3. 10.1186\/s41199-020-0050-3","journal-title":"Cancers Head Neck"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-154","article-title":"Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review","volume":"11","author":"Wei Y","year":"2022","unstructured":"Wei Y, He W, Sun W, et al.. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review. Transl Cancer Res. 2022, 11:2960-6. 10.21037\/tcr-22-154","journal-title":"Transl Cancer Res"},{"key":"ref8","article-title":"PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: a cautionary case report","volume":"62","author":"He L","year":"2022","unstructured":"He L, Zhuang Y, Zhang D, Tang Z. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: a cautionary case report. Transfus Apher Sci. 2022, 62:103603.","journal-title":"Transfus Apher Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx113","article-title":"Pembrolizumab associated hemophagocytic lymphohistiocytosis","volume":"28","author":"Shah D","year":"2017","unstructured":"Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017, 28:1403. 10.1093\/annonc\/mdx113","journal-title":"Ann Oncol"},{"key":"ref10","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report","volume":"6","author":"Sadaat M","year":"2018","unstructured":"Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. BMJ. 2018, 6:1.","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1159\/000539955","article-title":"A case report of immune checkpoint-related hemophagocytic lymphohistiocytosis and review of the literature","volume":"17","author":"Herman M","year":"2024","unstructured":"Herman M, Lee A, Fawcett S, Deodhare S. A case report of immune checkpoint-related hemophagocytic lymphohistiocytosis and review of the literature. Case Rep Oncol. 2024, 17:1.","journal-title":"Case Rep Oncol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1159\/000507281","article-title":"Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma","volume":"13","author":"Thummalapalli R","year":"2020","unstructured":"Thummalapalli R, Heumann T, Stein J, et al.. Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma. Case Rep Oncol. 2020, 13:508-14.","journal-title":"Case Rep Oncol"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0598-9","article-title":"Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports","volume":"7","author":"Noseda R","year":"2019","unstructured":"Noseda R, Bertoli R, M\u00fcller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunotherap Cancer. 2019, 7:1.","journal-title":"J Immunotherap Cancer"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1394543","article-title":"Hemophagocytic lymphohistiocytosis\/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study","volume":"14","author":"Patton L","year":"2024","unstructured":"Patton L, Monteith B, Heffernan P, Herzinger T, Wilson B. Hemophagocytic lymphohistiocytosis\/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study. Front Oncol. 2024, 14:11.","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051985","article-title":"Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study","volume":"12","author":"Diaz L","year":"2023","unstructured":"Diaz L, Jauzelon B, Dillies AC, Souder CL, Faillie JL, Maria ATJ, Palassin P. Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study. J Clin Med. 2023, 12:1985.","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-251052","article-title":"Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy","volume":"15","author":"Holmes Z","year":"2022","unstructured":"Holmes Z, Courtney A, Hiong A. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy. BMJ Case Reports. 2022, 15:e251052.","journal-title":"BMJ Case Reports"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0384-0","article-title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","volume":"6","author":"Hantel A","year":"2018","unstructured":"Hantel A, Garster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018, 6:73.","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2340144","article-title":"Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases","volume":"29","author":"Xu Z","year":"2024","unstructured":"Xu Z, Li H, Yu X, Luo J, Zhang Z. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases. Hematology. 2024, 29:10.1080\/16078454.2024.2340144","journal-title":"Hematology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1464","article-title":"Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy","volume":"13","author":"Rajapakse P","year":"2022","unstructured":"Rajapakse P, Andanamala H. Hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitor therapy. World J Oncol. 2022, 13:49-52. 10.14740\/wjon1464","journal-title":"World J Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398287-nivolumab-induced-hemophagocytic-lymphohistiocytosis-hlh-in-a-patient-with-metastatic-melanoma-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:41:04Z","timestamp":1761270064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398287-nivolumab-induced-hemophagocytic-lymphohistiocytosis-hlh-in-a-patient-with-metastatic-melanoma-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.95260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}